In Reply to Hurmuz and Ozyigit

To the Editor: We thank Dr Hurmuz for expressing interest in our recent report (1) and her cogent comments (2). Stereotactic body radiation therapy (SBRT) has indeed become a standard treatment for peripherally located, medically inoperable stage I non-small cell lung cancer (NSCLC). Local control rates from SBRT for such patients have generally been >90%, with regional lymph node control rates ranging from 85% to 90% (3, 4). Our previous pooled analysis of the STARS and ROSEL randomized studies (3) revealed estimated rates of locoregional control and overall survival (OS) at 3 years of 90% and 95% in the SBRT arms—indeed, the OS rates were better for SBRT than for surgery (79%).

https://ift.tt/2H0P7Yp